We work with sponsors leading the renaissance in psychedelic clinical development to navigate the nuances of psychedelic trials, efficiently and effectively.
Worldwide Clinical Trials has helped sponsors like you develop psychedelic programs for the treatment of psychiatric illnesses since 2017. Our teams supported one of the first industry-sponsored, global studies in psychedelics, and have since supported numerous programs, applying emerging science to operationalize studies quickly and practically. We’ve mastered the complex operational delivery of working with controlled psychedelic compounds in psychiatric indications like major depressive disorder, treatment-resistant depression, post-traumatic stress disorder, substance use disorders, and anorexia nervosa.
Christine Moore, PhD is Vice President, Scientific Solutions, Neuroscience at Worldwide Clinical Trials. She is an experimental psychologist by training and received her Ph.D. at Texas Tech University. With 25 years in drug development and commercialization, her experience extends from scientific to operational expertise with roles at the site level, in clinical monitoring and project management, scientific affairs, and commercialization planning.
Natalia has worked in clinical research for nearly 20 years, focusing primarily on neurology, psychiatry, pain, and pediatrics. Her experience includes small, intricate Phase I studies as well as large global Phase III programs. As Franchise Area Lead for Neuroscience, she provides operational oversight to neuroscience projects, working with bespoke teams to develop operational strategy and to mitigate risk.
Rolana Avrumson has more than 23 years’ clinical experience, 14 years’ experience in clinical trial research, and has worked for Worldwide Clinical Trials since May 2014. As the Vice President of Clinical Projects, her primary responsibilities include oversight of the operational and clinical conduct of assigned studies, including rater, CRA, and patient training; source eligibility reviews; data surveillance; sponsor reporting; and scale management. Ms. Avrumson has held significant roles in global and domestic phase I-IV trials in several indications with pediatric, adult, and geriatric populations including psychiatry, neurocognitive disorders, movement disorders, and various rare disease and pain indications. Ms. Avrumson has a master’s degree in rehabilitation counseling psychology with a specialty in substance dependence from the University at Albany, Albany, NY, and a bachelor’s degree in clinical psychology from Tufts University, Medford, MA.
Julia Forte holds over 25 years of clinical research industry experience, with a specialty in neuroscience. She has assisted in leading all Phases of clinical trials in large global environments across multiple therapeutic areas, with a focus in major depressive disorder and treatment resistant depression. Over the past few years, Julia has been involved in the oversight and management of trials with psychedelic compounds in treatment resistant depression, MDD, PTSD, and anorexia.
Olga Kolotilina began her career in medicine in 2000 as a psychiatrist before later entering into a career in clinical research as a CRA, moving into medical monitoring and focusing on psychiatric indications. Dr. Kolotilina is responsible for medical planning, medical input on regulatory submission, medical management and oversight of clinical trials, and she has a wide experience in Phase I-IV studies in CNS , including clinical trials in psychedelics.
Competition for psychedelic-experienced sites can be difficult. Use this checklist to help you select sites that set you up for success.Learn More
Careful patient selection is important for study success. Check out this resource to help you select the right patients.Learn More
We understand and can help you overcome the challenges and risks associated with developing and commercializing a psychedelic with scalable treatment in mind.
We partner with experienced clinical sites globally to support your enrollment goals, with careful consideration and standardization of a safe therapeutic setting and enrollment of the right patients.
Our in-house Clinical Assessment & Technologies team expertly select qualified independent efficacy raters and provide training across psychiatric indications, with careful attention in managing non-specific treatment effects and functional unblinding.
We’ve worked in neuroscience clinical development for over 30 years and have psychiatrists and psychedelic experts on staff to provide the expertise needed to execute your study. Our senior leaders are accessible for early and ongoing medical expertise and insights to enhance clinical development plans.
No two studies are alike—and we don’t treat them that way. We work with you to understand your study’s unique needs, leveraging our previous experience to guide us as we develop a new approach for you. We see every study as a collaboration, working together to advance your psychedelic program to new frontiers.
We’ve been a part of industry-sponsored psychedelic trials since they began. Our Psychedelic Center of Excellence has a comprehensive approach to the complex operational delivery of these trials and working with patients and sites for study success.
A crowded research space makes it difficult to weed the subjectivity out of the science—which demands a CRO with psychiatry know-how from the ground up and the top down. Our proven track record for patient recruitment and engaged investigator networks speaks volumes about our expertise in psychiatric trial development and execution.Learn More
Worldwide was founded to help improve research for neurology patients. Decades later, we’ve done it all, working on a dizzying number of compounds and indications in every phase. Now Worldwide is one of the few full-service CROs that provides integrated rater training, scale management, bespoke assessment development, and a broad range of other highly specialized consulting services in addition to our top-notch global network of study execution experts.Learn More
Our Cognitive Task Force and scale development work speak volumes about our commitment to Alzheimer’s and dementia research. At Worldwide, we design and execute rigorous, compassionate studies we’d be happy to have our own family and friends take part in, carefully protecting the patient experience and maintaining compelling data integrity to get products to market even in this competitive research space.Learn More
Rare neurological diseases each have unique hurdles for developing compelling outcomes assessments that can demonstrate efficacy with small patient populations. Worldwide is a leader in rare disease recruitment, novel endpoint development, and innovative study designs. We deliver specialty studies that apply our overarching knowledge in neurological conditions and rare diseases to thoughtful study designs, respecting patient communities and generating the data sponsors need to advance their compound to market.Learn More
Worldwide leads the way in best practice development for pain and addiction research. We have seen it all, which helps us offer the right blend of tried-and-true logistics, creative study designs, and thoughtful outcomes measures to augment objectivity in this otherwise nebulous field of research.Learn More
Senior Medical Director, Medical Affairs
Senior Director, Project Management
Senior Director, Therapeutic Strategy Lead, Neuroscience
Vice President, Central Nervous System Therapeutic Area Lead, Medical Affairs
Chief Development Officer
Executive Director, Project Management, Psychiatry and Neuroscience Rare Diseases
Senior Vice President, Project Management, Neuroscience
Executive Director, Project Management, Franchise Area Lead, Analgesia, Addiction, and Neurology Rare Disorders
Vice President, Scientific Solutions, Neuroscience
Executive Director, Project Management, Alzheimer’s Disease and other Dementias
Executive Director, Project Management, Neurology and Rare Diseases
Chief Medical and Scientific Officer
Vice President, Project Management, Psychiatry, Alzheimer’s Disease and other Dementias
Vice President, Neuroscience, Scientific Solutions
Executive Director, Project Management, Alzheimer’s Disease and other Dementias
Vice President, Project Management, Psychiatry and Neurology
Senior Vice President, Medical & Scientific Affairs
Vice President of Clinical Projects, Clinical Assessment Technologies